Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Utility of High-Throughput Sequencing of Immunoglobulin Genes for MRD in Lymphoid Malignancy in the Context of Current Immunotherapeutics

Imogen R Caldwell, Michael Ingbritsen, Yan Zhuang Yap, Mark R Dowling, Ing S Tiong, David A Westerman, Piers Blombery

Blood (2022) 140 (Supplement 1): 10731–10732.

https://doi.org/10.1182/blood-2022-162228

Published: 2022

Journal Articles

Computational Flow Cytometry Provides Accurate and Sensitive Measurable Residual Disease Assessment in Chronic Lymphocytic Leukemia

Phillip C Nguyen, Vuong Nguyen, Neil Came, David A Westerman

Blood (2022) 140 (Supplement 1): 12369–12370.

https://doi.org/10.1182/blood-2022-165649

Published: 2022

Journal Articles

Time-Limited Ibrutinib and Tisagenlecleucel Is Highly Effective in the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma, Including Those with TP53 Mutated and Btki-Refractory Disease: First Report of the Tarmac Study

Adrian Minson, Nada Hamad, Chan Y. Cheah, Constantine S. Tam, Piers Blombery, David A Westerman, Stephen Lade, David Ritchie, Rachel M Koldej, Mary Ann Anderson, Amit Khot, John F. Seymour, Molly Robertson, Imogen R Caldwell, Georgina L Ryland, Jing Xie, Huw Morgan, Michael Dickinson

Blood (2022) 140 (Supplement 1): 181–183.

https://doi.org/10.1182/blood-2022-160459

Published: 2022

Journal Articles

Clonal hematopoiesis, myeloid disorders and BAX -mutated myelopoiesis in patients receiving venetoclax for CLL

Piers Blombery, Thomas E. Lew, Michael A. Dengler, Ella R. Thompson, Victor S. Lin, Xiangting Chen, Tamia Nguyen, Ashish Panigrahi, Sasanka M. Handunnetti, Dennis A. Carney, David A. Westerman, Constantine S. Tam, Jerry M. Adams, Andrew H. Wei, David C. S. Huang, John F. Seymour, Andrew W. Roberts, Mary Ann Anderson

Blood (2022) 139 (8): 1198–1207.

https://doi.org/10.1182/blood.2021012775

Published: 2022

Includes: Supplemental data

Journal Articles

BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax

Victor S. Lin, Thomas E. Lew, Sasanka M. Handunnetti, Piers Blombery, Tamia Nguyen, David A. Westerman, Bryone J. Kuss, Constantine S. Tam, Andrew W. Roberts, John F. Seymour, Mary Ann Anderson

Blood (2020) 135 (25): 2266–2270.

https://doi.org/10.1182/blood.2020004782

Published: 2020

Includes: Supplemental data

Journal Articles

Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax

Piers Blombery, Ella R. Thompson, Tamia Nguyen, Richard W. Birkinshaw, Jia-nan Gong, Xiangting Chen, Michelle McBean, Rachel Thijssen, Thomas Conway, Mary Ann Anderson, John F. Seymour, David A. Westerman, Peter E. Czabotar, David C. S. Huang, Andrew W. Roberts

Blood (2020) 135 (10): 773–777.

https://doi.org/10.1182/blood.2019004205

Published: 2020

Includes: Supplemental data

Journal Articles

Intravital Microscopy Reveals Fundamental Differences in the Interaction of Stem Cells and T Acute Lymphoblastic Leukaemia with the Bone Marrow Microenvironment

Blood (2016) 128 (22): 5199.

https://doi.org/10.1182/blood.V128.22.5199.5199

Published: 2016

Journal Articles

Clinicopathological Features and Outcomes of Progression for Chronic Lymphocytic Leukaemia (CLL) Treated with the BCL2 Inhibitor Venetoclax

Thomas E Lew, Mary Ann Anderson, MBBS, Constantine S. Tam, MBBS, David C.S. Huang, MBBS, MRCP, PhD, Surender Juneja, MD FRCPA, David A Westerman, MBBS, FRACP, FRCPA, John F Seymour, Andrew W. Roberts, MBBS, PhD

Blood (2016) 128 (22): 3223.

https://doi.org/10.1182/blood.V128.22.3223.3223

Published: 2016

Journal Articles

International Validation of a Dithiothreitol (DTT)-Based Method to Resolve the Daratumumab Interference with Blood Compatibility Testing

Blood (2015) 126 (23): 3567.

https://doi.org/10.1182/blood.V126.23.3567.3567

Published: 2015

Journal Articles

Reproducible Diagnosis of Chronic Lymphocytic Leukemia (CLL) By Flow Cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation Project

Blood (2015) 126 (23): 4146.

https://doi.org/10.1182/blood.V126.23.4146.4146

Published: 2015

Journal Articles

Ependymal cells in cerebrospinal fluid: a traumatic occurrence

Paul Yeh, David A. Westerman

Blood (2015) 125 (12): 2005.

https://doi.org/10.1182/blood-2014-11-610477

Published: 2015

Journal Articles

Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy

Charlotte F. M. Hughes, Amit Khot, Christopher McCormack, Stephen Lade, David A. Westerman, Robert Twigger, Odette Buelens, Kate Newland, Constantine Tam, Michael Dickinson, Gail Ryan, David Ritchie, Colin Wood, H. Miles Prince

Blood (2015) 125 (1): 71–81.

https://doi.org/10.1182/blood-2014-07-588236

Published: 2015

Includes: Supplemental data

Journal Articles

A Complementary Role of High Throughput Sequencing and Multiparameter Cytometry for Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL):an European Research Initiative (ERIC) Study

Andy Rawstron, PhD, Claudia Fazi, PhD, Neus Villamor, MD PhD, Julio Delgado, MD PhD, Remi Letestu, MD PhD, Florence Cymbalista, MD, Carlos Palacio, Francesc Bosch, MD PhD, Ruth M De Tute, MSc, Stuart Liptrot, David O'Brien, FAMLs, Martin Spacek, MD, PhD, Johan Dobber, Arnon P. Kater, MD PhD, Peter C Gambell, David A Westerman, MBBS, FRACP, FRCPA, Asha Soosapilla, Stephen P. Mulligan, MBBS, PhD FRACP, FRCPA, Gerard Lozanski, MD, Ke Lin, PhD, Andrew R Pettitt, MRCP, PhD, Gabi Brachtl, Alexander Egle, MD, David W Williamson, PhD, Catherine M Sanders, PhD, Harlan Robins, PhD, Justin Boysen, Tait D. Shanafelt, MD, Curtis A. Hanson, MD, Jeffrey L. Jorgensen, MD PhD, William G. Wierda, MD PhD, Constance Yuan, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Laura Rassenti, PhD, H. Elizabeth Broome, MD, Thomas J. Kipps, MD PhD, Mathieu Hauwel, Iuri Marinov, Fiona E. Craig, MBBS, Nomdedeu Josep, Carol Moreno, MD, Olga Stehlikova, MSc., Michael Doubek, Sarka Pospisilova, Prof., Dr., PhD, Karl-Anton Kreuzer, MD, Michael Hallek, MD, Peter Hillmen, MBChB, PhD, Emili Montserrat, MD PhD, Paolo Ghia, MD

Blood (2014) 124 (21): 1976.

https://doi.org/10.1182/blood.V124.21.1976.1976

Published: 2014

Journal Articles

Incorporating High-Dose IV Methotrexate Into Initial Therapy Results In Lower Rates Of Central Nervous System (CNS) Relapse In Patients With High-Risk Diffuse Large B-Cell Lymphoma (DLBCL)

Chan Y Cheah, MBBS, FRACP, FRCPA, Kirsten Herbert, MD, BSci(Med), FRACP, PhD, Kacey O'Rourke, MBBS FRACP FRCPA, Glen Kennedy, MBBS FRACP FRCPA, Anupkumar George, MBBS FRACP FRCPA, Pasquale Fedele, MBBS, Shuh Ying Tan, MBBS, Stephen Opat, MBBS(Hons) FRACP FRCPA, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Max Wolf, MBBS, FRACP, FRCPA, Elchanan H. Januszewicz, MBBS FRACP FRCPA, Michael J. Dickinson, MBBS, FRACP, FRCPA, David A Westerman, MBBS, FRACP, FRCPA, H. Miles Prince, MBBS, FRACP, FRCPA, MD, Dennis A Carney, MBBS FRACP FRCPA, Simon J. Harrison, MBBS MRCP (uk) MRCPath (uk) PhD, Constantine S. Tam, MBBS, FRACP, FRCPA, MD, John F Seymour, MBBS, PhD, FRACP

Blood (2013) 122 (21): 4353.

https://doi.org/10.1182/blood.V122.21.4353.4353

Published: 2013

Journal Articles

Selective Bcl-2 Inhibition With ABT-199 Is Highly Active Against Chronic Lymphocytic Leukemia (CLL) Irrespective Of TP53 Mutation Or Dysfunction

Mary Ann Anderson, MBBS, FRACP, FRCPA, Constantine C.S. Tam, MBBS, FRACP, FRCPA, John F. Seymour, MBBS FRACP, Anthony Bell, David A Westerman, MBBS, FRACP, FRCPA, FFSc, Surender Juneja, MD, David C.S. Huang, MB, BS, MRCP, PhD, Andrew W. Roberts, MBBS, PhD

Blood (2013) 122 (21): 1304.

https://doi.org/10.1182/blood.V122.21.1304.1304

Published: 2013

Journal Articles

Flow Cytometric Screening of Novel Antigen Expression in T- ALL

David A Westerman, MBBS, FRACP, FRCPA, FFSc, Megan Wilson, MT, Brent L. Wood, MD, PhD, Michael J. Borowitz, MD, PhD, Greg Levin, MT

Blood (2012) 120 (21): 1436.

https://doi.org/10.1182/blood.V120.21.1436.1436

Published: 2012

Journal Articles

Surveillance PET-CT Scanning Is Useful in the First 18 Months Following Completion of Therapy for Patients with Diffuse Large B-Cell Lymphoma with IPI≥3.

Chan Y Cheah, MBBS, FRACP, FRCPA, Michael S Hofman, MBBS FRACP, Michael J. Dickinson, MBBS, FRACP, FRCPA, Andrew Wirth, MBBS, FRANZCR, David A Westerman, MBBS, FRACP, FRCPA, FFSc, Simon J. Harrison, MBBS MRCP (uk) MRCPath (uk) PhD, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Max Wolf, MBBS, FRACP, FRCPA, Elchanan H. Januszewicz, MBBS FRACP FRCPA, Kirsten Herbert, MD, BSci(Med), FRACP, PhD, Miles Prince, MD, FRACP, FRCPA, Dennis A Carney, MBBS FRACP FRCPA, David Ritchie, MBBS, FRACP, FRCPA, PhD, Rodney Hicks, MB BS, MD, FRACP, John F Seymour, MB, BS, PhD, FRACP

Blood (2012) 120 (21): 2652.

https://doi.org/10.1182/blood.V120.21.2652.2652

Published: 2012

Journal Articles

Utility of Flow Cytometry (FC) in the Assessment of Therapeutic Efficacy in Myelodysplastic Syndromes (MDS) After Therapeutic Intervention.

Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Peter Gambell, BSc, MHSM, Neil Came, MBBS, FRACP, FRCPA, Kevin Lynch, MB, BS, FFPM, John F. Seymour, MBBS, PhD, FRACP, Miles Prince, MBBS, MD, MRACMA, FRACP, FRCPA, David A Westerman, MBBS, FRACP, FRCPA

Blood (2009) 114 (22): 2767.

https://doi.org/10.1182/blood.V114.22.2767.2767

Published: 2009

Journal Articles

Complete molecular response of e6a2 BCR-ABL–positive acute myeloid leukemia to imatinib then dasatinib

David S. Ritchie, Michelle McBean, David A Westerman, Sergey Kovalenko, John F. Seymour, Alexander Dobrovic

Blood (2008) 111 (5): 2896–2898.

https://doi.org/10.1182/blood-2007-08-107508

Published: 2008

Journal Articles

Novel Methods for the Sensitive Detection of c- KIT D816V and Other Exon 17 Mutations in Patients with Mastocytosis.

Angela Y. Tan, PhD, David A. Westerman, MD, Kevin P. Lynch, MD, Grant A. McArthur, MD, PhD, Alexander Dobrovic, PhD

Blood (2005) 106 (11): 3273.

https://doi.org/10.1182/blood.V106.11.3273.3273

Published: 2005

NARROW

Utility of High-Throughput Sequencing of Immunoglobulin Genes for MRD in Lymphoid Malignancy in the Context of Current Immunotherapeutics

Computational Flow Cytometry Provides Accurate and Sensitive Measurable Residual Disease Assessment in Chronic Lymphocytic Leukemia

Time-Limited Ibrutinib and Tisagenlecleucel Is Highly Effective in the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma, Including Those with TP53 Mutated and Btki-Refractory Disease: First Report of the Tarmac Study

Clonal hematopoiesis, myeloid disorders and BAX -mutated myelopoiesis in patients receiving venetoclax for CLL

BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax

Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax

Intravital Microscopy Reveals Fundamental Differences in the Interaction of Stem Cells and T Acute Lymphoblastic Leukaemia with the Bone Marrow Microenvironment

Clinicopathological Features and Outcomes of Progression for Chronic Lymphocytic Leukaemia (CLL) Treated with the BCL2 Inhibitor Venetoclax

International Validation of a Dithiothreitol (DTT)-Based Method to Resolve the Daratumumab Interference with Blood Compatibility Testing

Reproducible Diagnosis of Chronic Lymphocytic Leukemia (CLL) By Flow Cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation Project

Ependymal cells in cerebrospinal fluid: a traumatic occurrence

Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy

A Complementary Role of High Throughput Sequencing and Multiparameter Cytometry for Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL):an European Research Initiative (ERIC) Study

Incorporating High-Dose IV Methotrexate Into Initial Therapy Results In Lower Rates Of Central Nervous System (CNS) Relapse In Patients With High-Risk Diffuse Large B-Cell Lymphoma (DLBCL)

Selective Bcl-2 Inhibition With ABT-199 Is Highly Active Against Chronic Lymphocytic Leukemia (CLL) Irrespective Of TP53 Mutation Or Dysfunction

Flow Cytometric Screening of Novel Antigen Expression in T- ALL

Surveillance PET-CT Scanning Is Useful in the First 18 Months Following Completion of Therapy for Patients with Diffuse Large B-Cell Lymphoma with IPI≥3.

Utility of Flow Cytometry (FC) in the Assessment of Therapeutic Efficacy in Myelodysplastic Syndromes (MDS) After Therapeutic Intervention.

Complete molecular response of e6a2 BCR-ABL–positive acute myeloid leukemia to imatinib then dasatinib

Novel Methods for the Sensitive Detection of c- KIT D816V and Other Exon 17 Mutations in Patients with Mastocytosis.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only